Sana Biotechnology, Inc. Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)
Sana Biotechnology, Inc. (SANA) reported Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill · last filed 2026-03-03
- Sana Biotechnology, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2024 was $0.00.
- Sana Biotechnology, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2023 was $0.00.
- Sana Biotechnology, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2022 was $0.00.
- Sana Biotechnology, Inc. impairment of intangible assets, indefinite-lived (excluding goodwill) for fiscal 2021 was $0.00.
| Period end | Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) 12 month |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2026-03-03 |
| 2023-12-31 | $0.00 10-K · filed 2024-02-29 |
| 2022-12-31 | $0.00 10-K · filed 2023-03-16 |
| 2021-12-31 | $0.00 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |